FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices

Reprint notice: This is a short digest based on public FDA information. Copyright remains with the original publisher.

The FDA issued a discussion paper on August 18, 2026 and requested feedback on regulatory considerations for generative AI-enabled medical devices, including risk assessment, premarket evaluation and postmarket monitoring.